Authors
Latest:
Practice-Changing Lung Cancer Data From the 2025 ASCO Annual MeetingStephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.
Latest:
Poulikos Poulikakos, PhD, on Combining Targeted Therapy and Immunotherapy in MelanomaPoulikos Poulikakos, PhD, discussed combining targeted therapy and immunotherapy for the treatment of patients with melanoma at the 16th International Congress of the Society for Melanoma Research.
Latest:
Kunal Rai, PhD, Discusses Genomic Alterations in Melanoma TherapyThe MD Anderson Cancer Center expert discussed how researchers are using genetic alterations to drive specific therapies at the 16th International Congress of the Society for Melanoma Research.
Latest:
Richard White, MD, PhD, Discusses His Research into Why Melanoma MetastasizesThe Memorial Sloan Kettering Cancer Center expert discussed a study he designed to discover why and how melanoma metastasizes, at the 16th International Congress of the Society for Melanoma Research.
Latest:
Kevin M. Sullivan, MD, Discusses Treatment Expansion in Lung CancerKevin M. Sullivan, MD, from the Northwell Health Cancer Institute, discussed how the options for treatment of patients with lung cancer have expanded greatly at the Annual New York Lung Cancers Symposium®.
Latest:
NSCLC Treatment: MET Exon 14 Skipping Mutations and RET RearrangementsBalazs Halmos, MD, and the Oncology Brothers discuss therapeutic practices for patients with NSCLC, highlighting how MET exon 14 skipping mutations and RET rearrangements inform treatment decisions.
Latest:
Brendon M. Stiles, MD, Discusses Low-Dose Radiation Therapy Along with ImmunotherapyThe thoracic surgeon from NewYork-Presbyterian Hospital discusses a trial at the institution in which they give low-dose radiation therapy along with immunotherapy at the Annual New York Lung Cancers Symposium®.
Latest:
Addressing Disparities Through the Enhancing Oncology Model and the Opportunity With Medically Integrated DispensingCancerNetwork spoke with AmerisourceBergen's Lisa Harrison, RPh, about how the new Enhancing Oncology Model and medically integrated dispensing factor into combating health disparities.
Latest:
ALLO-715, Off-the-Shelf CAR T-Cell Therapy, Produces Early Promise in Multiple MyelomaAn off-the-shelf CAR T-cell therapy that targets B-cell maturation antigen, ALLO-715, elicited responses in heavily pretreated patients with relapsed/refractory multiple myeloma in early findings from a first-in-human study presented at the 2020 ASH Meeting.
Latest:
Pembrolizumab Plus Chemoradiation Therapy Yields Promising Results for Patients with Unresectable, Locally Advanced NSCLCFollow up data from KEYNOTE-799 demonstrated a high overall response rate with no new safety signals for patients with unresectable, locally advanced, stage III non-small cell lung cancer.
Latest:
Matthew S. Davids, MD, MMSc, Discusses Extended Use of Venetoclax in CLLMatthew S. Davids, MD, MMSc, spoke about the benefit of venetoclax combinations in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Latest:
Treatment Options in RAI-refractory DTC in Second Line and BeyondLori Wirth, MD, discusses the role of cabozantinib in the second-line setting for patients with radioiodine-refractory differentiated thyroid cancer and reviews the results from the COSMIC-311 trial.
Latest:
Molecular Characterization and Treatment of Pancreatic Neuroendocrine TumorsONCOLOGY recently spoke with Ana Maria Cristina De Jesus-Acosta, MD, an assistant professor of oncology at Johns Hopkins University, about the molecular characterization and treatment of pancreatic neuroendocrine tumors.
Latest:
Taking a Patient-First Approach to Treatment in Chronic Lymphocytic LeukemiaAs developments in treatment options advance in chronic lymphocytic leukemia, Dr Pagel discusses the importance of finding a treatment for patients to deliver long-term outcomes that do not compromise tolerability.
Latest:
Multidisciplinary Team Is ‘Critical’ in Providing CAR T Therapy for Blood CancersTreatment with CAR T cells may allow patients with hematologic malignancies to recover more quickly compared with a transplant, says Andre Goy, MD.
Latest:
Breast Reconstruction in the Setting of Postmastectomy Radiotherapy: Controversies and DisparitiesBreast reconstruction improves quality of life, but providers must be aware of the risks and benefits of each reconstruction approach in the setting of postmastectomy radiotherapy.
Latest:
Breast Reconstruction in the Setting of Postmastectomy Radiotherapy: Controversies and DisparitiesBreast reconstruction improves quality of life, but providers must be aware of the risks and benefits of each reconstruction approach in the setting of postmastectomy radiotherapy.
Latest:
Next Generation of CAR-T Therapies in LymphomaExperts comment on the future of CAR T-cell therapy development and the use of dual CAR-T and CAR-T retreatment.
Latest:
Recurrent Small Cell Carcinoma of the Lung With Cutaneous Metastasis in BreastExperts present a case of recurrent small cell lung cancer presenting with a cutaneous metastatic nodule in the right breast.
Latest:
Samantha Jaglowski, MD, MPH, on Next Steps Regarding Tisagenlecleucel for Patients with DLBCLThe associate professor at The Ohio State University Comprehensive Cancer Center explained the goals for the future of the CAR T-cell therapy data in patients with DLBCL.
Latest:
Megan Kruse, MD, Discusses the Use of Biosimilars in Breast Cancer TreatmentThe hematology and medical oncology expert described the implementation of biosimilars into treating patients with breast cancer.
Latest:
Corey Speers, MD, PhD, Discusses Personalized Radiation Treatment and Genomic SignaturesThe assistant professor from the University of Michigan talked about personalizing radiation treatment in patients with breast cancer and how genomic signatures can be used to identify the radiation needs of patients.
Latest:
Nadine M. Tung, MD, Discusses Germline Testing in Patients with Breast CancerThe cancer risk and prevention expert discussed germline testing and the benefits it lends to patients with breast cancer.
Latest:
Bijal D. Shah, MD, on CAR T-cell therapy and mantle cell lymphomaBijal D. Shah, MD, discusses the progress made regarding CAR T-cell therapy and mantle cell lymphoma.
Latest:
Oral SERD Regimen May Prolong Efficacy in Second-Line Breast Cancer CareAdministering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Latest:
Madelaine Kuiper, MSN, NP, Discusses Rapid Development of HER2-Targeted TherapiesThe nurse practitioner from UCLA Health spoke about the expanding treatment options in this setting.
Latest:
Simon Rule, MD, PhD, on Long-Term Outcomes with Ibrutinib Versus Prior Treatment RegimensThe expert hematologist from Plymouth University Medical Center discussed the long-term outcomes of patients receiving ibrutinib for mantle cell lymphoma at the ASH Annual Meeting and Exposition.
Latest:
Jeff P. Sharman, MD, on Results from the ELEVATE TN Study in CLLThe Willamette Valley Cancer Institute and Research Center expert talks about the results of the ELEVATE TN trial at the ASH Annual Meeting and Exposition.
Latest:
Diego Villa, MD, FRCPC, Discusses Bendamustine and Rituximab as Induction Therapy in MCLDiego Villa, MD, FRCPC, elaborated on the progress made with bendamustine and rituximab as induction therapy for transplant eligible and ineligible patients with mantle cell lymphoma.
Latest:
Courtney DiNardo, MD, MSCE, on Enasidenib Plus Azacitidine in Newly Diagnosed AMLCourtney DiNardo, MD, MSCE, elaborated on interim phase II results regarding enasibenib plus azacitidine in patients with newly diagnosed acute myeloid leukemia, and the results from the QUAZAR trial.
